Quanta, IDT Sign Deal for Manufacture of microRNA Assays | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quanta BioSciences today announced a partnership with Integrated DNA Technologies for the manufacture of assays for quantifying microRNAs.

Under the terms of the deal, IDT will produce the assays and market them through an online catalog directly to customers of Quanta.

Financial and other terms of the deal were not disclosed.

Based in Gaithersburg, Md., Quanta develops reagents for PCR, qPCR, and cDNA applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.